# Merit Medical Launches the Resilience Through-the-Scope Esophageal Stent
Canonical URL: https://biopharmsignal.com/news/MMSI/merit-medical-launches-the-resilience-through-the-scope-esophageal-stent-0061b016
Ticker: MMSI
Company: Merit Medical
Source: Merit Medical
Published: 2026-03-16 13:25 EST
## Summary

New Resilience™ deployment system, anti-migration stent design, and unique stent sizes offer physicians control while enhancing treatment for patients with...

## Article Body
New Resilience™ deployment system, anti-migration stent design, and unique stent sizes offer physicians control while enhancing treatment for patients with esophageal fistulas and malignant strictures

March 16, 2026 09:25 ET | Source: Merit Medical Systems, Inc.

SOUTH JORDAN, Utah, March 16, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the US commercial release of the Resilience Through-the-Scope (TTS) Esophageal Stent.

The Resilience stent is the newest product in Merit’s Endoscopy portfolio, joining a comprehensive offering of treatment options for patients with disease in the esophagus. The new stent is indicated for treatment of esophageal fistulas and strictures (narrowing) caused by malignant tumors.

Esophageal cancer is the sixth most common cause of cancer deaths worldwide. 1 Symptoms of esophageal cancer include trouble swallowing, regurgitation, and chest pain. These gradually worsen over time, with an increase in pain when swallowing as the esophagus narrows from the growing cancer.

To care for this patient population, the Resilience stent was developed with proprietary anti-migration flanges to anchor the stent in place. 2,3 In addition, it is designed to demonstrate the greatest migration resistance among currently available TTS stents.

A single-handed deployment system provides clinicians with control for easy and accurate placement. 2 To meet a variety of clinical needs, Resilience is the only stent on the market offered in sizes 14 mm x 50 mm, 17 mm x 50 mm, and 20 mm x 50 mm. 2

Learn more about Resilience.

“The Resilience TTS Esophageal Stent fulfills an unmet need with its unique sizes, design, easy-to-use delivery system, and anti-migration properties,” said Stuart K Amateau, MD, PhD, Professor and Chief Division of Gastroenterology, Hepatology, and Nutrition at the University of Minnesota Medical Center in Minneapolis, MN.

The Resilience stent addresses several well-known clinical disadvantages of currently available TTS esophageal stents,” said Martha G. Aronson, Merit’s President and Chief Executive Officer. “This launch signifies another step forward in the rapidly growing TTS stent-technology market. At Merit, we continually strive to understand clinical needs and deliver innovation that advances the care patients receive.”

1. Huang et al. 2021. “Global Burden, Risk Factors, and Trends of Esophageal Cancer: An Analysis of Cancer Registries from 48 Countries.” Cancers (Basel) 13, no. 1 (Jan): 141. doi: 10.3390/cancers13010141.

2. Bench Data on File.

3. Mozafari et al. 2018. “Migration Resistance of Esophageal Stents: The Role of Stent Design.” Comput Biol Med 100 (Sept): 43–49. doi: 10.1016/j.compbiomed.2018.06.031.

ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,600 people worldwide.

CONTACTS

PR/Media Inquiries Sarah Comstock Merit Medical +1-801-432-2864 | sarah.comstock@merit.com

Investor Inquiries Mike Piccinino, CFA, IRC ICR Healthcare +1-443-213-0509 | mike.piccinino@icrhealthcare.com
## Recent Company News
- 2026-07-02 20:05 EST — [Merit Medical Systems to Announce Second Quarter 2026 Results on July 30, 2026](https://biopharmsignal.com/news/MMSI/merit-medical-systems-to-announce-second-quarter-2026-results-on-july-30-2026-f3864c0a) — Source: Merit Medical
- 2026-05-19 13:15 EST — [Merit Medical Shareholders Elect Scott R. Ward to Board of Directors](https://biopharmsignal.com/news/MMSI/merit-medical-shareholders-elect-scott-r-ward-to-board-of-directors-b8f2f33a) — Source: Merit Medical
- 2026-05-08 13:25 EST — [Merit Medical to Participate in the Bank of America Healthcare Conference](https://biopharmsignal.com/news/MMSI/merit-medical-to-participate-in-the-bank-of-america-healthcare-conference-20d54d66) — Source: Merit Medical
- 2026-04-30 20:05 EST — [Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance](https://biopharmsignal.com/news/MMSI/merit-medical-reports-first-quarter-2026-results-and-updates-full-year-guidance-651680cc) — Source: Merit Medical
- 2026-04-02 22:00 EST — [Merit Medical Systems to Announce First Quarter 2026 Results on April 30, 2026](https://biopharmsignal.com/news/MMSI/merit-medical-systems-to-announce-first-quarter-2026-results-on-april-30-2026-1af622dd) — Source: Merit Medical
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)